Anti-CD19 CAR T Cells in Autoimmune Encephalitis: Inflammation Controlled, Neurodegeneration Unchecked?

Area of Science:

• Neuroimmunology
• Cellular Therapy
• Autoimmune Disorders

Background:

• Autoimmune encephalitis poses significant challenges, often requiring novel therapeutic approaches.
• Refractory cases, such as anti-diacylglycerol lipase alpha (DAGLA) antibody-mediated disease, highlight the need for effective treatments.
• Chimeric antigen receptor (CAR) T cell therapy has emerged as a promising strategy for B cell-mediated autoimmune conditions.

Purpose of the Study:

• To report the extended follow-up of the first patient with refractory anti-DAGLA antibody-mediated autoimmune encephalitis treated with CAR T cell therapy.
• To assess the long-term efficacy of CAR T cell therapy in maintaining remission and controlling autoantibodies.
• To investigate the impact of CAR T cell therapy on neurodegeneration in the context of sustained B cell suppression.

Main Methods:

• Administration of chimeric antigen receptor (CAR) T cells targeting B cells in a patient with anti-DAGLA antibody-mediated autoimmune encephalitis.
• Longitudinal clinical assessment, including neurological examinations and autoantibody monitoring.
• Evaluation of neuroimaging and other biomarkers to assess neurodegeneration.

Main Results:

• The patient achieved a stable, relapse-free clinical course with persistent suppression of anti-DAGLA autoantibodies following CAR T cell therapy.
• Despite sustained control of B cell-mediated inflammation, the patient exhibited progressive neurodegeneration.
• A dissociation was observed between immune quiescence and ongoing structural decline in the central nervous system.

Conclusions:

• CAR T cell therapy is highly effective in extinguishing B cell-mediated inflammation and controlling autoantibodies in autoimmune encephalitis.
• CAR T cell therapy alone may not be sufficient to prevent or reverse neurodegeneration in conditions with both inflammatory and degenerative components.
• Further research is needed to address the neurodegenerative aspects of such disorders, potentially through combination therapies.